in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants. Bone Marrow Transplantation 2008 41, 851–859. Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schafer-Eckardt K, Beyer J, Kiehl M, and Zander AR. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol. 2003; 82: 336-342. Lim ZY, Ho AY, Ingram W, Kenyon M, Pearce L, Czepulkowski B, Devereux S, Duarte RF, Pagliuca A, Mufti GJ. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors <strong>for</strong> myelodysplastic syndromes. Br J Haematol. 2006; 135:201-9. Laport GG, Sandmaier BM, Storer BE, Scott B, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman FJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin PT, Maloney DG, Blume KG, Storb RF. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation <strong>for</strong> adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Bone Marr Transpl 2008; 14: 246- 55. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, Bacigalupo A, Beelen D, Reiffers J, Devergie A, Alessandrino E, Mufti GJ, Barge R, Sierra J, Ruutu T, Boogaerts M, Falda M, Jouet JP, Niederwieser D, de Witte T; Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group. Retrospective comparison of reduced-intensity conditioning and conventional high-dosse conditioning <strong>for</strong> allogeneic hematopoietic stem celle transplantation using HLA-identical sibling donor in myelodysplastic syndromes.Blood. 2006; 108:836-46. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation <strong>for</strong> older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010 Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y, Tanosaki R, Takahashi S, Matsushima T, Atsuta Y, Hamajima N, Kasai M, Kato S. Value of chemotherapy be<strong>for</strong>e allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor <strong>for</strong> myelodysplastic syndrome. Leukemia 2005; ;19:396-401. Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M, Prentice HG, Garg M, Yin JA, Byrne J, Russell NH, and Mufti GJ. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol. 2002; 119: 144-154. Runde V, De Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, Niederwieser D, Labopin M, Walter NM, Bacigalupo A, Jacobsen N, Ljungman P, Carreras E, Kolb HJ, Aul C, and Apperley J. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group <strong>for</strong> Blood and Marrow Transplantation. Bone Marrow Transplant.1998; 21: 255-261. Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, Davies SM, Lazarus HM, Bredeson CN, Marks DI, Canals C, Boogaerts MA, Goldman J, Champlin RE, KeatingA, Weisdorf DJ, de Witte TM, and Horowitz MM. Bone marrow transplantation from HLA-identical siblings as treatment <strong>for</strong> myelodysplasia. Blood 2002; 100: 1997-2004. 44
Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, Chauncey TR, Storb R, Deeg HJ. Myeloablative vs nonmyeloablative allogeneic transplantation <strong>for</strong> patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20: 128-35. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322-8. Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court, Kelsey S, Amess JA, Rohatiner AZ, Lister TA, and Barnett, MJ. Durable remissions of myelodysplastic syndromeand acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol. 2003; 21: 3060-3065. Witherspoon RP, Deeg HJ, Storer B, Anasetti C, Storb R, and Appelbaum FR. Hematopoietic stem-cell transplantation <strong>for</strong> treatment-related leukemia or myelodysplasia. J Clin Oncol. 2001; 19: 2134-41. de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, Ruutu T, Ljungman P, Gratwohl A, Runde V, Niederwieser D, van Biezen A, Devergie A, Cornelissen J, Jouet JP, Arnold R, and Apperley J. Haematopoietic stem cell transplantation <strong>for</strong> patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group <strong>for</strong> Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000 ;110:620-30. 45
- Page 1 and 2: Rekommandationer for knoglemarvstra
- Page 3 and 4: Vævstyper og terminologi Ved valg
- Page 5 and 6: 3.valg: 9/10 allel forligelig ubesl
- Page 7 and 8: Petersdorf EW et al: Major-histocom
- Page 9 and 10: Sygdomsspecifikke overvejelser & kr
- Page 11 and 12: Non myeloablativ stamcelletransplan
- Page 13 and 14: Akutte Leukæmier ALL hos voksne AL
- Page 15 and 16: En metaanalyse af 7 studier, hvor a
- Page 17 and 18: Højrisikofaktorer • Fænotype: N
- Page 19 and 20: Kemoterapi Hoelzer, D.F (1993). The
- Page 21 and 22: unrelated transplant in first compl
- Page 23 and 24: ALL hos børn 5% blaster i knoglema
- Page 25 and 26: i det nordamerikanske register, af
- Page 27 and 28: Risikogrupper for AML i 1. CR Lavri
- Page 29 and 30: Autolog KMT Litteraturen på områd
- Page 31 and 32: Gale, R.P., Horowitz, M.M., Weiner,
- Page 33 and 34: myelogenous leukemia in first compl
- Page 35 and 36: AML hos børn
- Page 37 and 38: Eapen M, Rubinstein P, Zhang MJ, Ca
- Page 39 and 40: Point Parameter 0 0.5 1 1.5 2 Blast
- Page 41 and 42: *) Specielt i denne gruppe gælder
- Page 43: Kantarjian H, O'Brien S, Cortes J,
- Page 47 and 48: tiltagende. Patienter med RC og hø
- Page 49 and 50: Donor leukocyte infusion after hema
- Page 51 and 52: � Konstitutionelle symptomer, for
- Page 53 and 54: Responskriterier ved CML Responstyp
- Page 55 and 56: patienter, som statistisk set vil h
- Page 57 and 58: Mauro,M.J. (2006) Defining and mana
- Page 59 and 60: LYMFOMER Lymfoblastært lymfom Lymf
- Page 61 and 62: Der er ingen data, der indicerer at
- Page 63 and 64: BURKITT'S LYMFOM Senest revideret:
- Page 65 and 66: Hoelzer D, Ludwig W-D, , Thiel E et
- Page 67 and 68: Der er ikke indikation for autolog
- Page 69 and 70: sequential chemotherapy in poor-ris
- Page 71 and 72: af immunosuppressiv beh. og DLI og
- Page 73 and 74: following high-dose sequential chem
- Page 75 and 76: Marginal Zone Lymfom Senest revider
- Page 77 and 78: Rezvani AR, Storer B, Maris M et al
- Page 79 and 80: eskriver også sammenhæng mellem i
- Page 81 and 82: HCT ved refraktær sygdom (Verdonck
- Page 83 and 84: transplantation for lymphoprolifera
- Page 85 and 86: Perifere T-Celle Lymfomer Senest re
- Page 87 and 88: Referencer: Evens AM, Gartenhaus RB
- Page 89 and 90: Hodgkin Lymfom (HL) Senest revidere
- Page 91 and 92: Patienter med progressiv sygdom ell
- Page 93 and 94: Transplant, 12,172-183. Anderlini,P
- Page 95 and 96:
Allogen KMT 1. HLA-identisk søsken
- Page 97 and 98:
Referencer Definition Bacigalupo A,
- Page 99 and 100:
Paroxysmal Nocturn Haemoglobinuri,
- Page 101 and 102:
Autolog transplantation Myelomatose
- Page 103 and 104:
Cavo M, Tosi P, Zagmani E, Cellini
- Page 105 and 106:
Myelofibrose Idiopatisk myelofibros
- Page 107 and 108:
Introduktion Retransplantation af b
- Page 109 and 110:
Den samlede konklusion kunne være,
- Page 111 and 112:
Thalassæmier Senest revideret nove
- Page 113 and 114:
thalassæmifri overlevelse på 66%
- Page 115 and 116:
Kronisk granulomatøs sygdom Senest